JSJan Peter Sutter

Jan Peter Sutter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Peter Sutter has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Ansgar W. Lohse

    I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Dominic Wichmann

    Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Hans Pinnschmidt

    Center for Experimental Medicine, Institute for Medical Biometry & Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Jan Kempski

    I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Lorenz Kocheise

    I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Martin Christner

    Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications

Latest Publications

  • Open Access

    Reply to: Challenges in interpreting the role of gentamicin in treatment of invasive listeriosis: immortal timebias and confounding

    by Jan P. Sutter, Lorenz Kocheise, Jan Kempski, Martin Christner, Dominic Wichmann, Hans Pinnschmidt, Stefan Schmiedel, Ansgar W. Lohse, Samuel Huber, Thomas Theo Brehm


  • Open Access

    Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis

    by Jan P. Sutter, Lorenz Kocheise, Jan Kempski, Martin Christner, Dominic Wichmann, Hans Pinnschmidt, Stefan Schmiedel, Ansgar W. Lohse, Samuel Huber, Thomas Theo Brehm

    Purpose: Listeria monocytogenes causes severe bacterial infections with the highest mortality rate among foodborne pathogens in Europe. Combination treatment with ampicillin and gentamicin is recommended for invasive manifestations. However, evidence to support this treatment approach remains limited due to a lack of randomised controlled trials. To explore this critical issue further, we conducted this retrospective, single-center study. Methods: We identified all patients hospitalized with invasive listeriosis at the University Medical Center Hamburg-Eppendorf between 2009 and 2020 and analyzed the effect of gentamicin combination treatment versus monotherapy on 90-day mortality. Results: In total, 36 patients with invasive listeriosis were included, of which 21 patients received gentamicin combination treatment and 15 received monotherapy. The mean age-adjusted Charlson Comorbidity Index (aaCCI) value was lower in the gentamicin combination treatment group (5.4 vs. 7.4). Neurolisteriosis was more common in the gentamicin group (81% vs. 20%). The 90-day mortality was with significantly lower in the gentamicin combination treatment group (10%) compared to the monotherapy group (60%). Multivariable cox regression analysis, adjusted for a propensity score computed based on neurolisteriosis, aaCCI and sex, revealed a significantly reduced hazard ratio of 0.07 (95% CI: 0.01–0.53, p = 0.01) for 90-day mortality for the gentamicin combination treatment. Conclusion: This retrospective study highlights the benefit of gentamicin combination treatment in reducing the 90-day mortality rate among patients with invasive listeriosis. The high prevalence of monotherapy in this study cohort raises concerns about the adequacy of antibiotic therapy in clinical practice.


  • Open Access

    Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR

    by Flaminia Olearo, Dominik Noerz, Fabian Heinrich, Jan Peter Sutter, Kevin Roedel, Alexander Schultze, Julian Schulze Zur Wiesch, Platon Braun, Lisa Oesterreich, Benno Kreuels, et al.

    Background: SARS-CoV-2 molecular diagnostics is facing material shortages and long turnaround times due to exponential increase of testing demand. Objective: We evaluated the analytic performance and handling of four rapid Antigen Point of Care Tests (AgPOCTs) I-IV (Distributors: (I) Roche, (II) Abbott, (III) MEDsan and (IV) Siemens). Methods: 100 RT-PCR negative and 84 RT-PCR positive oropharyngeal swabs were prospectively collected and used to determine performance and accuracy of these AgPOCTs. Handling was evaluated by 10 healthcare workers/users through a questionnaire. Results: The median duration from symptom onset to sampling was 6 days (IQR 2-12 days). The overall relative sensitivity was 49.4%, 44.6%, 45.8% and 54.9 % for tests I, II, III and IV, respectively. In the high viral load subgroup (containing >10 6 copies of SARS-CoV-2 /swab, n=26), AgPOCTs reached sensitivities of 92.3% or more (range 92.3%-100%). Specificity was 100% for tests I, II and IV and 97% for test III. Regarding handling, test I obtained the overall highest scores, while test II was considered to have the most convenient components. Of note, users considered all assays, with the exception of test I, to pose a significant risk for contamination by drips or spills. Discussion: Besides some differences in sensitivity and handling, all four AgPOCTs showed acceptable performance in high viral load samples. However, due to the significantly lower sensitivity compared to RT-qPCR, a careful consideration of pro and cons of AgPOCT has to be taken into account before clinical implementation.